109 Medicines And Vaccines Now In Development For HIV/AIDS America's pharmaceutical research companies are testing 109
medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 20th anniversary of "World AIDS Day" - a global awareness campaign that originated at the 1988 World Summit of Ministers of
Health on Programmes for AIDS Prevention.
Source: www.medicalnewstoday.comViroPharma Submits Supplemental Biologics License Application For Cinryze(TM) To Treat Acute Attacks Of Hereditary Angioedema ViroPharma Incorporated (Nasdaq: VPHM) announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze(TM) C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE). The sBLA is based on a re-analysis and resubmission of data from a pivotal Phase 3 acute treatment study of Cinryze and interim data from an ongoing open label acute study of the drug.
Source: www.medicalnewstoday.comFDA Approves Duramed's Synthetic Conjugated Estrogens A Vaginal Cream Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream. SCE-A Vaginal Cream is a plant-derived local estrogen product indicated for the treatment of moderate to severe vaginal dryness and pain with intercourse, both of which are symptoms of vulvar and vaginal atrophy due to menopause.
Source: www.medicalnewstoday.comVical Receives Milestone Payment From Merck & Co., Inc. Triggered By Planned Initiation Of Investigational Cancer DNA Vaccine Trial Vical Incorporated (Nasdaq: VICL) announced the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate license agreement.
Source: www.medicalnewstoday.comTorreyPines' NGX426, An Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints In Reducing Capsaicin Induced Pain In Healthy Subjects TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain resulting from normally non-painful stimuli to the skin) compared to placebo following intradermal injections of capsaicin in a human experimental model of cutaneous pain, hyperalgesia and allodynia.
Source: www.medicalnewstoday.comGeoVax's Phase 2a HIV/AIDS Vaccine Human Trials To Begin In North And South America GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America. These trials are conducted in collaboration with The National Institutes of
Health (NIH), and the HIV Vaccine Trials Network (HVTN).
Source: www.medicalnewstoday.comS*BIO Advances JAK2 Inhibitor SB1518 Into Phase 1/2 Clinical Trial In Australia For The Treatment Of Chronic Idiopathic Myelofibrosis S*BIO Pte Ltd announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
